Maternal Serum Alpha-fetoprotein Level May Predict the Presence of Morbid Adherent Placenta

September 6, 2019 updated by: rasha medhat abdul-hady

Alpha-fetoprotein as a Biochemical Marker in Prediction of Placenta Acreta Increta Percreta

The aim of the study is to compare between alpha-fetoproteine as a biological marker and between ultrasound and Doppler in prediction of morbid adherent placenta.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

in pregnant women withe previous cesarean section, placenta previa and ultrasonographic finding of an abnormally adherent placenta dose maternal serum alpha-fetoprotein predict prenataly the presence of morbid adherent placenta accurately?

Study Type

Observational

Enrollment (Anticipated)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Cairo, Egypt
        • Ain shams university maternity hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 37 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

150 pregnant women from 28wk to full term who are attending outpatient clinic and emergency room ain shams university maternal hospital

Description

Inclusion Criteria:

  • pregnant women with history of scarred uterus

    • plcenta previa covering the scar of previous caesarean section as diagnosed by 2DU/S
    • Gestational age from 28wks to full term

Exclusion Criteria:

  • pregnant women with fetus with congenital anomalies

    • pregnant women with ovarian swelling
    • pregnant women with medical disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Non_adherent plcenta
placenta separated within 15 minutes after delivery of fetus
Adherent placenta
placenta dosenot separated within 15 minutes after delivery of fetus
Diagnostic test: Serum alpha-fetoproteine
Midtrimesteric serum alpha-fetoprotein mesurment with 2D US and 3D power Doppler with MS US scan .
Other Names:
  • 2D Ultrasound
  • 3D power doppler with MS US

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maternal serum alpha-fetoprotein
Time Frame: From 28weeks to 37 weeks
ng/ml or MOM(Multiple of the median)
From 28weeks to 37 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

rasha medhat abdul-hady

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2017

Primary Completion (Anticipated)

August 30, 2019

Study Completion (Anticipated)

August 30, 2019

Study Registration Dates

First Submitted

August 29, 2019

First Submitted That Met QC Criteria

September 6, 2019

First Posted (Actual)

September 9, 2019

Study Record Updates

Last Update Posted (Actual)

September 9, 2019

Last Update Submitted That Met QC Criteria

September 6, 2019

Last Verified

September 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AFP_AP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Placenta Accreta

Clinical Trials on Serum alpha-fetoproteine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe